Other substances

Selinexor

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
9
 AI-suggested references
3
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Preprint 		in silico

one of the top drugs and compounds identified by ViroTreat

 May/17/2020

AI-suggested references

Link Publication date
Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor
Mar/25/2021
Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.
Apr/27/2021
Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment
Jan/28/2022
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response
Oct/27/2021
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
Jun/17/2020
Exportin 1 inhibition as antiviral therapy
Mar/10/2022
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Nov/20/2021
Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease
Jul/05/2021
Computational screening of potential drugs against COVID-19 disease: the Neuropilin-1 receptor as molecular target
Jan/05/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04355676 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 Withdrawn Phase 2 Apr/30/2020 Aug/30/2020
  • Alternative id - XPORT-CoV-1002
  • Interventions - Drug: Selinexor
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE)
NCT04534725 COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; Recruiting Phase 3 Dec/17/2020 Dec/01/2021
  • Alternative id - Peter Mac ID 20/135
  • Interventions - Drug: Interferon alfa|Drug: Selinexor|Drug: Lenzilumab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 2282
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)|incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing|incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .|incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records|time to clinical improvement or discharge from hospital assessed using medical records|ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool|ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records|ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records|ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale|ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records|ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR|ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records|ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records|ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.|ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records|ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.|ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.|ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.|ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records|ARM 3: Time to clinical improvement assessed using medical records.|ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 3: change to clinical condition assessed with Karnofsky Performance score|ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale|ARM 3: Time to all-cause mortality|ARM 3:Duration of hospitalisation assessed using medical records|ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.|ARM 3: Duration of oxygen supplementation (days). assessed using medical records.|ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)|ARM 3: Safety and tolerability of selinexor using relevant medical records|ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records|ARM 4: Incidence of all cause death by day 28 and 60|ARM 4: Time to all-cause mortality|ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 4: Incidence of ARDS assessed using medical records|ARM 4: incidence of HLH. assessed using medical records|ARM 4: Duration of hospitalisation. assessed using hospital medical records.|ARM 4: Proportion discharged from hospital. assessed using medical records|ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records|ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records|ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.|ARM 4: Incidence and duration of ICU admission. assessed using medical records|ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records|ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.|ARM 4: incidence of non-invasive ventilation. assessed using medical records|ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.|ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records|ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records|ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records|ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.
NCT04349098 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Completed Phase 2 Apr/17/2020 Oct/05/2020
  • Alternative id - XPORT-CoV-1001|2020-001411-25
  • Interventions - Drug: Selinexor|Other: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 190
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale|Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7|Percentage of Participants With at Least a 1-Point Improvement in the Ordinal Scale|Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)|Overall Death Rate|Rate of Mechanical Ventilation (RMV)|Rate of Intensive Care Unit (ICU) Admission|Length of Hospitalization|Change From Baseline in C-reactive Protein (CRP) Levels|Change From Baseline in Ferritin Levels|Change From Baseline in Lactate Dehydrogenase (LDH) Levels|Changes From Baseline in Blood Plasma Cytokines Levels-Interleukin-6 (IL-6)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
Export (.csv)